All In Biotech

NDA 022029 · Hisamitsu Pharm CO

Salonpas

Menthol, Methyl Salicylate · Topical

Last checked: Nov 20, 2026Latest source record: Oct 6, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Feb 20, 2008

Approved uses

3

Original approval plus efficacy supplements

Registered trials

107

20 Phase 3, 5 recruiting

FAERS reports

37,817

29,306 serious, 7,326 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 13, 2026.

INDICATIONS & USAGE SECTION

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • SALONPAS · MENTHOL 3%; METHYL SALICYLATE 10% · PATCH, TOPICAL · Over-the-counter
  • SALONPAS · MENTHOL 3%; METHYL SALICYLATE 10% · PATCH, TOPICAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Menthol" as an intervention, any sponsor and status, largest first.

All 107 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective8,004
  • pain7,680
  • fatigue7,245
  • rheumatoid arthritis6,543
  • rash6,293
  • abdominal discomfort6,172
  • off label use6,019
  • systemic lupus erythematosus6,006
  • alopecia5,903
  • glossodynia5,881
  • pemphigus5,836
  • swelling5,561

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004432
2005490
2006454
2007606
2008749
2009561
2010794
20111,184
2012905
2013330
2014391
2015620
20161,082
20171,194
20181,762
20191,883
20202,343
20213,135
20223,363
20233,470
20245,038
20254,363
20262,666

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 369 on PubMed

Sponsor: Hisamitsu Pharm CO

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.